Home › Community-Acquired Pneumonia › NCT02735707
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
REMAP-CAP PLATFORM INCLUSION CRITERIA: 1. Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission with: 1. symptoms or signs or both that are consistent with lower respiratory tract infection AND 2. Radiological evidence of new onset consolidation (in patients with pre-existing radiological changes, evidence of new infiltrate) 2. Up to 48 hours after ICU admission, receiving organ support with one or more of: 1. Non-invasive or Invasive ventilatory support; 2. Receiving infusion of vasopressor or inotropes or both PLATFORM EXCLUSION CRITERIA: 1. Healthcare-associated pneumonia: 1. Prior to this illness, is known to have been an inpatient in any healthcare facility within the last 30 days 2. Resident of a nursing home or long term care facility 2. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment 3. Previous participation in this REMAP within the last 90 days REMAP-COVID PLATFORM INCLUSION CRITERIA 1\. Adult patients (≥ 18 years) admitted to hospital with acute illness due to suspected or proven pandemic infection. REMAP-COVID PLATFORM EXCLUSION CRITERIA 1. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment 2. Patient is expected to be discharged from hospital today or tomorrow 3. More than 14 days have elapsed while admitted to hospital with symptoms of an acute illness due to suspected or proven pandemic infection. 4. Previous participation in this REMAP within the last 90 days DOMAIN-SPECIFIC ELIGIBLE CRITERIA: Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org).
About the study
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.
The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia.
In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19.
REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.
What is being tested
- Ceftriaxone (drug)
- Moxifloxacin or Levofloxacin (drug)
- Piperacillin-tazobactam (drug)
- Ceftaroline (drug)
- Amoxicillin-clavulanate (drug)
- Standard course macrolide (drug)
Sponsor: UMC Utrecht · Participants: 20,000 · Started: Apr 11, 2016
Contact the study team
Official record on ClinicalTrials.gov — NCT02735707
Locations in the U.S.
| Florida | University of Florida, Jacksonville |
| Georgia | Augusta University, Augusta (Not yet recruiting) |
| Illinois | University of Illinois Health, Chicago |
| Louisiana | Tulane Medical Center, New Orleans (Not yet recruiting) |
| Michigan | University of Michigan, Ann Arbor |
| New York | Memorial Sloan Kettering Cancer Center, New York |
| North Carolina | Wake Forest Baptist Health, Winston-Salem (Not yet recruiting) |
| Ohio | The Ohio State University Wexner Medical Center, Columbus |
| Oregon | Oregon Health and Science University, Portland |
| Pennsylvania | University of Pittsburgh Medical Centre, Pittsburgh |
| Rhode Island | Brown University - Rhode Island Hospital, Providence (Not yet recruiting) |
Conditions
- Community-Acquired Pneumonia
- Flu
- Post-COVID Conditions (Long COVID)
- Pneumonia
- Lung Diseases
- Respiratory Tract Infections
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.